CapLaw-2025-09

On 29 January 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, opened the 2025 Initial Public Offering (IPO) season and announced the launch of its IPO on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The company’s most advanced R&D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a).…